November 17, 2012, Quezon City Hall, 41 specialists, 360 patients…..The American Association of Clinical Endocrinologists Philippines held its annual Endocrine Awareness Day via a medical mission called “A G.O.O.D. Day”.
February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate
Chevy Chase, MD— In an effort to provide clarity to the confusion surrounding the human chorionic gonadotropin (hCG) diet, The Hormone Foundation, the public education affiliate of The Endocrine Society, today published, “Myth vs. Fact: The Human Chorionic Gonadotropin (hCG) Diet.” The fact sheet explains how hCG is intended to work in the body and the inherent risks in using hCG to lose weight.
November 9, 2011 (Rockville, Maryland) — The US FDA has issued a safety communication and updated the prescribing information for the cholesterol-lowering agent fenofibric acid (Trilipix, Abbott), stating that the drug may not lower the risk of major cardiovascular events . This is based on data from the ACCORD Lipid trial, in which the combination of fenofibrate plus simvastatin was compared with simvastatin alone in patients with type 2 diabetes mellitus.
On Friday, September 9, the United States Food and Drug Administration (FDA) reviewed the long term safety and efficacy of all approved bisphosphonates. Safety concerns discussed included esophageal cancer, osteonecrosis of the jaw (ONJ) and atypical fractures of the femur